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Congenital hypersensitivity to vitamin K antagonists due to FIX
propeptide mutation at locus -10: a (not so) rare cause of
bleeding under oral anticoagulant therapy in Switzerland
Abstract
QUESTION UNDER STUDY: In most countries hypersensitivity to vitamin K antagonists (VKA) is
considered to be a rare congenital bleeding diathesis. It occurs in patients with FIX propeptide mutations
at locus -10. We present a Swiss family with two patients who suffered major bleedings under oral
anticoagulant treatment in the presence of therapeutic or subtherapeutic INR levels and abnormally
prolonged aPTT. In both patients a mutation in the propeptide of FIX at locus -10 with substitution of
alanine by threonine (Ala-10Thr) was found. In one patient FIX clotting activity was found to be
severely reduced (2%). The observed bleeding tendency is related to this--compared to the other vitamin
K dependent factors (FII, FVII, FX)--excessively and disproportionately low level of FIX. Three
generations of this family were tested for propeptide mutations, which are transmitted in an
X-chromosomal recessive mode of inheritance. Apart from the two symptomatic male patients we found
another male with the mutation who has not been exposed to VKA, six female carriers and four potential
male carriers in the fourth generation who have not been tested. A founder effect for this mutation has
been previously described for cases in Switzerland and Germany. CONCLUSION: FIX propeptide
mutation-associated hypersensitivity to VKA is a rare occurrence in Switzerland. The severity of
associated bleeding complications and the reversible nature of the bleeding diathesis may nonetheless
warrant increased awareness on the part of primary care physicians in Switzerland.
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Question under study: In most countries hyper-
sensitivity to vitamin K antagonists (VKA) is con-
sidered to be a rare congenital bleeding diathesis.
It occurs in patients with FIX propeptide muta-
tions at locus -10. 
Patients, method and results: We present a Swiss
family with two patients who suffered major
bleedings under oral anticoagulant treatment in
the presence of therapeutic or subtherapeutic
INR levels and abnormally prolonged aPTT. In
both patients a mutation in the propeptide of FIX
at locus -10 with  substitution of alanine by threo-
nine (Ala-10Thr) was found. In one patient FIX
clotting activity was found to be severely reduced
(2%). The observed bleeding tendency is related
to this – compared to the other vitamin K de-
pendent factors (FII, FVII, FX) – excessively and
disproportionately low level of FIX. Three gener-
ations of this family were tested for propeptide
mutations, which are transmitted in an X-chro-
mosomal recessive mode of inheritance. Apart
from the two symptomatic male patients we
found another male with the mutation who has
not been exposed to VKA, six female carriers and
four potential male carriers in the fourth genera-
tion who have not been tested. A founder effect
for this mutation has been previously described
for cases in Switzerland and Germany. 
Conclusion: FIX propeptide mutation-associ-
ated hypersensitivity to VKA is a rare occurrence
in Switzerland. The severity of associated bleed-
ing complications and the reversible nature of the
bleeding diathesis may nonetheless warrant in-
creased awareness  on the part of primary care
physicians in Switzerland. 
Key words: Factor IX gene; oral anticoagulation;
bleeding; coumarin sensitivity
Summary
Oral anticoagulant therapy (OAT) with vita-
min K antagonists (VKA) is indicated for the pre-
vention and treatment of arterial and venous
thromboembolism [1]. Due to inter-individual
variability of vitamin K intake, vitamin K resorp-
tion, vitamin K metabolism and metabolic path-
ways relevant for the synthesis and posttransla-
tional modification of coagulation factors, clinical
response to OAT is highly variable. OAT thus re-
quires individualised dosing regimes and drug
monitoring. A highly relevant adverse drug effect
of OAT is so-called “major bleeding”. Major
bleeding is frequently defined as bleeding that is
intracranial or retroperitoneal or necessitates
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List of abbreviations
Ala Alanine
Glu Glutamine  
F Coagulation factor
FIX PM Factor IX propeptide mutation
INR International normalised ratio
OAT Oral anticoagulant therapy 
Thr Threonine
VKA Vitamin K antagonists
VKA-HS Vitamin K antagonist hypersensitivity
aPTT Activated partial thromboplastin time
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transfusion, requires hospitalisation and/or leads
to death. Its incidence varies according to the def-
inition that is adopted, the indication for OAT,
the intensity of OAT and the length of therapy. In
anticoagulated patients the reported incidence of
major bleeding is 1–7 patients/100 patient years
or 1–7% (fatal bleeding approximately 0.5%) [2].
Vitamin K antagonists inhibit coagulation by
limiting the availability of biologically active vita-
min K through inhibition of hepatic g-carboxy-
lase, an enzyme involved in posttranslational
modification of coagulation factors which is nec-
essary for biological function. This enzyme’s ac-
tivity requires biologically active vitamin K as an
obligatory cofactor. Anticoagulation with VKA
thus leads to reduced bioavailability of vitamin K
and reduced posttranslational modification of vi-
tamin K-dependent coagulation factors. The lat-
ter results in an altered three-dimensional struc-
ture of vitamin K-dependent coagulation factors
(FII, FVII, FIX and FX). The more rigid three-di-
mensional conformation of these non-carboxy-
lated coagulation factors is associated with inhib-
ited coagulation through their reduced capacity
to bind to and interact with activated surfaces 
[3–6].
In rare instances OAT-related bleeding is as-
sociated with a mutation of the factor IX (FIX)
gene. Two propeptide mutations have been de-
scribed at locus -10: Ala(GCC)-10Val(GTC) and
Ala(GCC)-10Thr(ACC) [7, 8]. The propeptide
sequence at locus -10 plays an important role in
the anticoagulant effect of VKA, since it contains
the binding site for hepatic g-carboxylase [9]. In
the presence of a mutation at the propeptide locus
-10, the binding of hepatic g-carboxylase to the
FIX protein is markedly reduced. This reduced
binding capacity has no clinical implications
under normal circumstances when sufficient vita-
min K is present, since the FIX levels will still be
within or only irrelevantly below the normal
range. However, when patients with propeptide
mutations are orally anticoagulated the lack of bi-
ologically active vitamin K combined with re-
duced binding of g-carboxylase to the coagulation
profactors results in a reversible clinically relevant
bleeding diathesis days to weeks after initiation of
VKA treatment. This bleeding diathesis is due 
to a rapid fall in FIX clotting activity (FIX:C),
which falls to a disproportionately low level com-
pared with the clotting activity of the other vitamin
K-dependent coagulation factors. In fact, FIX:C
levels fall so low that laboratory data mimic ac-
quired haemophilia B [8]. As this bleeding disor-
der becomes manifest only in the presence of VKA,
it has been referred to as “hypersensitivity to vita-
min K antagonists” (VKA-HS). This term has re-
cently been extended to other genetic variations
such as point mutations of the CYP2C9, which
result in bleeding diatheses due to overactivity of
coumarins [10]. However, in the present study the
term VKA-HS will refer to mutations in the fac-
tor IX propeptide only.
When patients with either of the mutations of
FIX described above are treated with VKA, the
bleeding diathesis is not detected by routine mon-
itoring of the international normalised ratio
(INR). The INR can be within or even below the
targeted value at the time of bleeding. However,
the sudden and disproportionately severe fall in
FIX levels (<= 3%) induced by OAT leads to per-
sistent abnormal prolongation of activated partial
thromboplastin time (aPTT). VKA treated pa-
tients may present a prolonged aPTT. The sever-
ity of aPTT prolongation differs from patient to
patient and depends on the laboratory methodol-
ogy used. By “abnormal” we mean a prolongation
that is unusual for the concurrent INR with a
given methodology. The high morbidity and mor-
tality associated with VKA treatment-related
bleeding, and the possibility of detecting patients
at risk by monitoring aPTT, has led to debate re-
garding the utility of screening all patients under
VKA [11–13]. The main argument against screen-
ing is the presumed low prevalence of the muta-
tion. We here report on the fourth and fifth Swiss
patients with an Ala-10Thr mutation, who both
presented with major bleeding under OAT. They
belong to a family with one other proven hetero -
zygote male (who has not been anticoagulated to
date) and six women who are proven carriers of
this X-linked recessive trait.
The purpose of this paper is to inform col-
leagues in Switzerland of the existence, frequency
and pathobiology of this genetic mutation and to
review issues such as treatment options for acute
bleeding, anticoagulation of affected individuals
and genetic testing in family members in the light
of current data. 
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Subjects and methods
Subjects: The index patient was a 70-year-old (JU),
highly active man in good general health who had to un-
dergo aortic valve replacement due to severe aortic steno-
sis. A porcine aortic valve xenograft was successfully im-
planted. The immediate postoperative course was unre-
markable and the patient was discharged 10 days later to a
cardiac rehabilitation clinic with haemoglobin of 9 g/dL.
His postoperative medications included OAT with phen-
procoumon (planned for 3 months), aspirin, diuretics
(spironolactone and loop diuretics), a beta-receptor
blocker, an angiotensin-converting enzyme inhibitor and
paracetamol. Shortly after starting cardiac rehabilitation
his condition deteriorated. He developed progressive and
very painful swellings of soft tissues, muscles and joints on
legs and arms, together with bilateral pleural effusions.
When this complications arose the patient’s INR was 1.6;
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the platelet count was normal (182 G/L). He was read-
mitted to the University Hospital of Zurich for further
investigation. The analgesic treatment with non-steroidal
anti-inflammatory drugs was immediately stopped. All
recorded INR values (range 1.5–2.5) had been in or just
below the therapeutic range. His haemoglobin at the
time of readmission was 8.1 g/dL. Despite daily blood
transfusions this value dropped to 6.3 g/dL on day three
of the hospitalisation. The neurological examination and
pulse status of the extremities were normal. Echocardio -
graphy and Doppler sonography of the heart and great
vessels revealed normal cardiac and graft function and 
no thrombosis of the great veins. A bleeding compli -
cation was suspected when the initially non-discoloured
swellings turned into clinically evident haematomas and
extensive testing was initiated in a search for a coagula-
tion disorder (figure 1). 
Family history: The family history revealed one
brother and one sister previously exposed to OAT. The
brother (WU), a farmer, had to be rehospitalised 5 weeks
after a successful operative fixation of a left-sided trau-
matic patella fracture at the age of 56 years, due to severe
muscle and joint bleeding of both lower extremities
under OAT. His haemoglobin was 6.1 g/dL and he re-
ceived packed erythrocyte transfusions. The patient
slowly recovered after OAT was stopped. 
Coagulation assays: Coagulation testing for patient JU
was performed at the Coagulation Laboratory of Zurich
University Hospital, an ISO 17025 accredited institution.
Coagulation tests (activators, suppliers and remarks are
given in parentheses) were run on a Dade Behring (DB),
Coagulation System (DB, Marburg, Germany): aPTT
(Actin FS, DB), INR (Innovin, DB), thrombin time
(bovine thrombin, Diagnotec, Liestal, Switzerland; in-
house assay), FVIII:C and FIX:C (Pathromtin SL; DB,
aPTT-based assay), FII:C, FVII:C and FX:C (Innovin;
DB, Quick-based assay), FXIII (Bercichrom FXIII, DB,
functional assay), fibrinogen (Thrombin, DB, functional
assay), Tinaquant D-dimer (Roche Diagnostics). The
FIX inhibitor test was performed according to the
Bethesda method [14]. 
Molecular genetic analysis of the FIX gene: Exon 2 of
the FIX gene was analysed by amplification of a 161 bp
fragment using the primers 5’-TTTCATGAT-
GTTTTCTTTTTTGC-3’ (nt 6270-6293) and 5’-
TACATTCTCTCTAAGGTTCC-3’ (nt 6410-6430).
Amplified fragments were sequenced by means of the
dideoxynucleotide chain termination method and the se-
quenase version 2.0 DNA sequencing kit (US Biochemi-
cal) [8, 15]. 
Figure 1
Extremities of the
index patients with
demarcated
haematomas resem-
bling haemophilia B
photographed six
days after diagnosis.
Results
Subjects: In the index patient, coagulation
studies revealed an abnormally prolonged aPTT
of 78 s (normal range 26–36 s), an INR of 2.1
under phenprocoumon therapy, elevated fibrino-
gen of 6.3 g/L (normal range 1.5–4 g/L)) and
slightly elevated D-dimers of 1.7 μg/mL (normal
range <0.5) (see table 1). Coagulation factor
analysis revealed a markedly decreased FIX (2%),
whereas FII and FVII were concordantly reduced
to OAT (46 and 29% respectively). Other factors
(factors V, VIII, XIII and von Willebrand) were
within normal limits or not determined (FX). 
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Acquired (antibody-induced) haemophilia B was
excluded by negative test for FIX inhibiting anti-
bodies (Bethesda test). In view of the laboratory
test results a genetic alteration of the FIX propep-
tide was suspected. Oral anticoagulation with
phenprocoumon was stopped. In view of the
severity of the bleeding, the need to stop the ac-
tive bleeding rapidly and the potential risk of
thromboembolism associated with other treat-
ment forms, we chose to administer two doses of
factor IX concentrate (3000 IU of Immunine
STIM plus [Baxter, Switzerland] followed 12
hours later by another dose of 1800 IU) intra-
venously. The patient subsequently recovered
slowly but consistently from this painful bleeding
disorder without recurrence. 
Family history: A review of the hospital records
from the index patient’s brother (WU) revealed
that the INR was consistently within the thera-
peutic range, whereas the aPTT was abnormally
prolonged to 95s. No further coagulation factor
measurements were performed at that time
(1996). An extended family history revealed a sis-
ter (AU) who had undergone abdominal hysterec-
tomy for cervical cancer at the age of 46 and re-
ceived short-term OAT for three months postop-
eratively. No bleeding complication occurred.
Three other siblings and their children had never
received OAT to date, or suffered from bleeding
disorders. Whole blood was obtained from three
generations of family members, after obtaining
written informed consent, and analysed for FIX
mutations (figure 2).
Molecular genetic analysis of the FIX gene: We
found the previously described genetic mutation
of the FIX gene, Ala[GCC]-10Thr[ACC],  in the
index patient (JU) and his brother (WU), both
with a bleeding history under OAT. One further
heterozygote male and six female “carriers” were
detected in the family. Apart from one female car-
rier who was exposed to OAT without a bleeding
complication, no other individuals have been ex-
posed to anticoagulation in the past. The pedigree
and patient history are depicted in figure 2. 
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JU,1936KU,1935 MU,1937 WU,1937 PU,1937 AU,1937
Index patient
Severe bleeding under OAT Severe bleeding under OAT Uneventful OAT
?
???
?
SU,1970 CU,1974
? ? ??
Figure 2
Circles are used for
females, squares for
males. Healthy indi-
viduals are depicted
in bright grey, af-
fected males in black
and heterozygote car-
rier females in bright
grey circles with an
internal dot. Descen-
dants possibly af-
fected with an un-
known genetic status
are striped and have
added question
marks. Only family
members with (possi-
bly) affected descen-
dants are followed to
the next generation.
Family pedigree
Discussion
The cases in context: We describe two patients
with the threonine variant of a FIX propeptide
mutation at locus -10 (Ala-10Thr; the wild type
alanine is replaced by a threonine [figure 3]). Nei-
ther patient manifested a clinically relevant bleed-
ing tendency in the absence of OAT. Both suffered
“major bleeding” events shortly after OAT initia-
tion and both had therapeutic or even subthera-
peutic INR and an abnormally prolonged aPTT
at the time of bleeding. 
In one patient (JU) the FIX:C level was meas-
ured shortly after the bleeding complication be-
came manifest and was found to be very low (2%).
This disproportionately low FIX:C level is re-
sponsible for the abnormally prolonged aPTT
and the acquired bleeding diathesis. He recovered
well after cessation of OAT and transient substitu-
tion of FIX concentrate, and has remained in very
good health with stable and normalised haemo-
globin for more than 12 months now (report of
primary care physicians).  
FIX levels were not measured in the second
patient at the time of bleeding, which occurred in
1996 – prior or just concomitant to the descrip-
tion of FIX propeptide mutations. In view of the
positive family history, diagnosis of the propeptide
mutation was made retrospectively by genetic
analysis.
What therapeutic options are available 
in the event of acute bleeding?
We chose to treat our patient (JU) with FIX
concentrate, since this treatment option instantly
corrects the bleeding tendency without reducing
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the level of anticoagulation and is associated with
minimal prothrombotic risk (only FIX:C is cor-
rected while the anticoagulant effects related to
low FII, FVII and FX are unaltered). In our view
this was desirable as the patient had recently re-
ceived a prosthetic heart valve. The major disad-
vantage of this treatment approach is its high cost.
Since the patient’s valve was of biological origin,
long-term anticoagulation was not necessary and
the patient could be discharged from hospital
under anti-aggregation treatment by aspirin with-
out anticoagulation. 
Other therapeutic options for acute bleeding
include vitamin K given intravenously or orally,
fresh frozen plasma (FFP) and prothrombin com-
plex concentrates (PCC). The low cost of vitamin
K in this case was outweighed by the prothrom-
botic risk due to reversal of anticoagulation, poor
predictability of response and slow treatment re-
sponse (several hours). FFP and PCC also have an
immediate effect, but cost and prothrombotic risk
need to be considered. FFP cannot be used in pa-
tients at risk of left heart decompensation related
to fluid overload. PCC, on the other hand, have a
low risk of fluid overload but are more expensive
and potentially more prothrombotic than FFP.
How can a mutation in a propeptide affect
FIX clotting activity?
Propeptides are cleaved prior to the secretion
of “mature” coagulation factors by the hepato-
cyte. The question thus arises of how a domain
that is no longer present in the circulating coagu-
lation factor can affect its biological activity. Fig-
ures 3 and 4 help to understand the pathophysiol-
ogy of VKA-HS. The liver is the main source of
plasma FIX. The FIX gene is located on the X
chromosome and harbours eight exons depicted
by yellow rectangles in figure 3 (DNA level) [3].
The gene translates into distinct domains includ-
ing a signal peptide (encoded by exon 1), a pro -
peptide (exon 2), a gla domain (exon 2), and the
serine protease domain (exons 7 + 8). The FIX
signal peptide targets the preproprotein to the 
endoplasmatic reticulum, where post-translatio-
nal modification occurs at the glutamyl residues
(glu, represented in figure 3 and figure 4 by 
yellow circles). The glu residues are thereby
transformed into gla residues (represented by
green or partially green circles in figure 3 and
 figure 4) with the aid of hepatic g-carboxylase, a
vitamin K-dependent enzyme. The carboxylation
status of FIX – like that of all vitamin K-depen-
dent coagulation factors – correlates with biologi-
cal activity. In the presence of biologically active
vitamin K g-carboxylation is “processive”. This
involves an all-or-nothing phenomenon: a mole-
cule either becomes carboxylated at all possible
sites (human FIX has 12 such glutamyl sites) or
remains non-carboxylated. High carboxylation
renders the molecule biologically active, whereas
low carboxylation status results in inactive vita-
min K-dependent coagulation factors [16]. 
The anticoagulant effect of VKA is due to
 diminished activity of g-carboxylase in the ab-
sence of vitamin K. VKA treatment also disrupts
“processivity”, resulting in non- or only partially
g-carboxylated FIX [5]. The low or absent 
Figure 3
Model of vitamin K antagonist hypersensitivity (VKA-HS) in
patients with Ala (-10)3Thr FIX propeptide mutation.
This figure illustrates features of Ala (10)3Thr FIX-PM at the
DNA level (yellow background) and at the protein level in
the absence (blue background) or presence of VKA (purple
background). Wild type FIX is depicted in the left column
with Ala (10)3Thr FIX-PM in the right column. The strength
of g-carboxylase (g-COOH) binding to the propeptide is indi-
cated by the size of the double headed arrows, whereas car-
boxylase activity is symbolised by the size of the single
headed arrows.
DNA level:The left represents the wild type FIX gene. The
right depicts the relevant point mutation at basepair 6346
(depicted by a pink bar) in the propeptide domain (depicted
in orange).   
Protein level: Wild type FIX(alanine at locus -10, left column)
permits optimal g-COOH binding (large double headed
arrow) and activity (large single headed arrow), resulting in
complete g-carboxylation status (illustrated by 4 green cir-
cles) and normal coagulation activity of the secreted FIX in
the absence of VKA (blue background). In the presence of
VKA treatment (purple background), g-carboxylase activity
(smaller single headed arrow) and consecutively FIX activ-
ity are reduced, resulting in the desired anticoagulation.
VKA-HS (tyrosine at locus -10 in the FIX-PM [right column])
results in normal or nearly normal g-carboxylation status
and coagulation factor activity in the absence of VKA treat-
ment (blue background). However, in the presence of VKA
treatment (purple background) the diminished g-COOH/FIX*
propeptide interaction related to the point mutation (see
small white double headed arrow) and the absence of 
biologically active vitamin K result in severely reduced 
g-carboxylation (yellow or partially yellow circles) and 
concordantly reduced FIX clotting activity. 
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g-carboxylation status leads to an altered three-
dimensional structure of the coagulation factor, 
to impaired binding to activated surfaces and
thereby to anticoagulation. 
How frequent are FIX propeptide mutations?
Studies from Great Britain, the Netherlands,
and Germany screened 1679 blood donors with-
out finding an affected individual. This suggests a
frequency of VKA-HS of below 1 in 1000. With
our two cases, five patients with symptomatic
VKA-HS have been described in Switzerland [6,
17, 18], two with the Ala3Val and three (includ-
ing our patients) with the Ala3Thr mutation
variant at locus 10 in the FIX propeptide. Al-
though intensive inquiry about the patient’s fam-
ily history did not reveal a relationship between
the present family and previously described cases
[6, 18], we cannot rule out some distant kinship in
earlier generations. From the reported cases the
prevalence of VKA-HS due to mutations in the
factor FIX propeptide in Switzerland can be esti-
mated at approximately 1:1’000’000. The real
prevalence is most probably even higher, due to
underdiagnosis. Assuming that approximately 1%
of the entire population is anticoagulated at any
point in time (based on the incidences of the three
main causes of OAT: atrial fibrillation, venous
thromboembolism and valvular heart disease),
and given that the mutation is only diagnosed in
patients under OAT, we extrapolate a prevalence
of the FIX propeptide mutation of above
1:100’000, possibly of 1:10’000.
A founder effect has been shown to exist in
five previously described patients from Germany
and Switzerland with the threonine variant of FIX
PM. The original “founder” may have come from
Switzerland. This would explain why a mutation
that is rare elsewhere is “not so rare” in Switzer-
land [15].
How can the mutation be diagnosed?
Given the suspected frequency of the muta-
tion, screening of the general population might
not be a successful strategy [11–13]. A simple
strategy might be to perform an aPTT in all pa-
tients with bleeding complications under VKA
treatment. If the aPTT is found to be abnormally
prolonged (whilst the INR might be in the target
range or even below), a VKA-HS might be sus-
pected. All laboratories can perform a 1:1 mixing
study with normal pooled plasma which, in the
event of normalisation of the INR (or aPTT),
rules out an inhibitor. In our view, further investi-
gation is warranted in the case of bleeding in
VKA-treated patients in the presence of a thera-
peutic or near therapeutic INR and an abnor-
mally prolonged aPTT, and where an inhibitor is
ruled out by mixing studies.
Specialised laboratories can measure activities
of individual clotting factors and perform in-
hibitor assays which will provide results sugges-
tive of a propeptide mutation: FIX far below the
expected range for an anticoagulated patient (all
patients for whom we found results in the litera-
ture had FIX:C values below or equal to 3% with
other vitamin K-dependent factors in the range of
15–60% in the presence of a normal FV:C); a
Bethesda assay for an acquired FIX inhibitor was
negative. 
Finally, VKA-HS can be confirmed and fam-
ily testing can be discussed. Given the high risk of
bleeding associated with this mutation the rele-
vance of identifying affected individuals is high.
However, the basic principles of genetic testing
(such as patient autonomy, informed consent, no
testing of minors, amongst others) must be re-
spected (www.samw.ch) [19]. 
It must be borne in mind that analysis of co-
agulation factor levels is not helpful in patients
with a history of bleeding under VKA treatment
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Figure 4
Plasma levels of vitamin K-dependent coagulation
 factors: Wild type FIX (left column) and FIX of patients
with a FIX-PM (FIX*; right column) are depicted in the
absence (blue background) and presence of VKA treat-
ment (purple background). The amino acid sequence of
circulating wild type FIX and FIX* is identical, the differ-
ence lying in the carboxylation status of the protein. In
the absence of VKA treatment the FIX clotting activities 
in both conditions are normal or subnormal. Only in the
presence of VKA treatment do FIX-PM patients acquire
disproportionately low factor levels. The disproportion-
ately low FIX levels translate into the abnormally pro-
longed aPTT observed in these patients. The percentages
after the respective molecules indicate plasmatic clotting
activity. 
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in whom the treatment was stopped or reversed
some time previously, since FIX levels return to
normal within days to weeks after VKA with-
drawal or vitamin K administration. In the ab-
sence of VKA the diagnosis thus relies uniquely
on detection of the mutation by the molecular
 biological approach.
Can affected individuals be anticoagulated?
Anticoagulation of patients with FIX propep-
tide mutations is associated with a high risk of
complications. Hence, depending on the indica-
tion to anticoagulate, alternatives to OAK should
be sought. In non-valvular atrial fibrillation as-
pirin has been shown to induce a 25% reduction
in the risk of stroke and major vascular events in
patients without prior stroke or TIA, with a num-
ber needed to treat of 1/100 [20]. In patients anti-
coagulated for venous thromboembolism low
molecular weight heparins are a potential alterna-
tive to VKA. In patients with an imperative indi-
cation for anticoagulation, such as those with me-
chanical heart valves, one can consider replacing
the mechanical valve with a bioprosthesis. A case
report from Denmark described a patient with a
mechanical valve who was anticoagulated with
warfarin despite having a propeptide mutation
[21]. The patient was managed by titrating anti-
coagulant treatment to FIX levels of 8–16%.
These levels were based on the observation that
haemophilia B patients rarely have thromboem-
bolic events, and on the hypothesis that FIX levels
slightly above the haemophilic range are protec-
tive of thromboembolism without the bleeding
risk of haemophilia. Currently phase II and phase
III trials are under way on direct oral anti-IIa and
anti-Xa. Such VKA alternatives might become
available in the near future, given that these drugs
have proven their efficacy and safety in the long-
term anticoagulation setting.
What about female carriers?
At present very little is known about the risk
of oral anticoagulation in female carriers. In the
literature we found one female carrier who was
anticoagulated with VKA due to atrial fibrillation.
While she had no bleeding complication, her FIX
decreased to a minimum of 16% [17]. In our man-
uscript we report on the patients’ heterozygote
sister who underwent three months of oral anti-
coagulation without bleeding complications. This
may suggest that the heterozygous mutation is
biochemically only subtly overt and clinically
silent due to one compensating normal allele.
However, as the allele dominance might not be
similar in all heterozygote females the risk of
OAK should be weighed against the expected
benefit. If VKA therapy must be prescribed we
recommend close monitoring of anticoagulation
including aPTT and FIX levels. 
In conclusion, we present in this study a Swiss
family with a recently described missense muta-
tion of the FIX propeptide (Ala-10Thr) which is
associated with severe bleeding complications
under OAT. Major bleeding in any patient under
OAT should be investigated; the presence of an
abnormally prolonged aPTT should prompt
 further investigations. An abnormally increased
aPTT in the presence of therapeutic or near ther-
apeutic INR levels is the key element in establish-
ing the relevant diagnosis. Treatment is aimed at
reversing the haemorrhagic diathesis and depends
on the indication for OAT. A disproportionate fall
in FIX:C as compared to other vitamin K-depen-
dent coagulation factors causes this congenital
bleeding diathesis, also referred to as hypersensi-
tivity to VKA. Inheritance of the disorder is X-
chromosomal recessive. This syndrome can be
classified as a special form of haemophilia B
which manifests itself only under OAT. With 
nine proven cases and four untested but poten-
tially affected juvenile males, our findings indicate
13.03.2006 30.03.2006 22.04.2006 25.04.2006 27.04.2007 28.04.2006 03.05.2006
Preop visit Discharge Readmission normal range
Haemoglobin g/dl 14.8 9.0 6.3 7.5 9.3 10 11.5 13.4–17.0
Thrombocytes (G/l) 235 211 283 286 362 374 408 143–400
Quick (%) 106 29 30 31 25 59 79 70–120
INR (ratio) 1 2.2 2.1 2.1 1.6 1.4 1.2 n.a.
aPTT (s) 29 76 78 53 38 34 26–36
Fibrinogen (g/l) 3.4 5.7 6.2 1.5–4.0
D-dimer (μg/ml) 0.6 1.7 <0.50
FII:C (%) 46 106 60–150
FVII:C (%) 29 60 60–150
FIX:C (%) 2 18 26 29 50–200
FX:C (%) 68 60–150
Abbreviations and remarks: not applicable (n.a.), factor II clotting activity (FII:C), factor XIII functional activity (FXIII), 
von Willebrand factor ristocetin cofactor activity (vWF) 
Table 1
Laboratory results of the index patient (JU).
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a relatively higher prevalence in Switzerland of a
disorder whose potentially grave consequences
and reversible nature warrant increased awareness
on the part of primary care physicians.
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